# Albemarle Corporation (ALB) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ALB/thesis · /stocks/ALB/memo

## Financial Snapshot

---
step: "04"
title: "Financial Quality & Adversarial Sweep"
ticker: ALB
company: "Albemarle Corporation"
source: coverage-next-full
created: 2026-05-28
---

### Step 04 — Financial Quality & Adversarial Sweep: ALB

#### Key Findings

- **GAAP accounting is largely conservative and standard** for the industry; revenue recognition follows shipment / delivery, no signs of channel stuffing or revenue acceleration [S1].
- **Impairment charges in 2024 ($1.03B) and 2025 ($280M)** were appropriate response to lithium price collapse — Kemerton Train 3 and Ketjen pre-sale carrying-value marks [S2]. Conservative impairment posture, not aggressive.
- **One material historical concern: FCPA settlement (2023, $103M)** related to pre-2010 payments in Vietnam/India/Indonesia. Company self-reported and remediated; independent compliance monitor was imposed [S3]. Risk: governance overhang, not ongoing material loss.
- **Net signal: positive on financial quality, with one significant historical compliance scar.**

#### Implications for Thesis and Valuation

Earnings quality through the cycle is **better than the headline numbers suggest**. The 2024–2025 GAAP losses are heavily weighted by non-cash impairments — underlying operating cash flow remained positive ($702M and $1,282M respectively) even at the bottom of the lithium cycle [S4]. This is critical for a Commodity/Upstream story: ALB demonstrated the ability to generate cash through a 90%+ price collapse, which de-risks the downside scenarios.

The FCPA settlement creates a small but persistent governance risk premium that should be reflected as ~50–100 bps additional cost of equity vs. a clean specialty-chemicals comp.

#### Objective

Assess earnings quality, accounting choices, restatements, and conduct the mandatory Adversarial Research Sweep (short reports, investigations, lawsuits, governance concerns).

#### Narrative Analysis

**Earnings quality scorecard:**

| Test | Result | Comment |
|------|--------|---------|
| OCF vs. Net Income | OCF >> NI in down years (2024: $702M OCF vs. ($1,179M) NI; 2025: $1,282M OCF vs. ($511M) NI) [S4] | Positive — losses are non-cash |
| Receivables vs. Revenue trend | Receivables tracking revenue declines proportionally [S1] | No buildup; clean |
| Inventory vs. Revenue | Inventory days elevated in 2024 (160+ days) as production exceeded demand; normalizing in 2025–2026 [S1] | Cyclical, not aggressive |
| SBC as % of OCF | SBC $40M / OCF $1.28B = 3% [S4] | Low; healthy |
| Capex vs. D&A | 2025 capex $590M vs. D&A $659M (capex < D&A — discipline) [S4] | Positive — investing below replacement |
| Goodwill vs. Equity | Goodwill $1,500M vs. Equity $9,533M = 16% [S1] | Manageable |
| Working-capital changes | Negative WC reversal in 2025 was OCF-positive ($580M) — inventory drawdown [S4] | One-time tailwind |

**Restatements / audit issues:** None material in 2020–2025 period [S1]. Auditor: PricewaterhouseCoopers (continuing engagement).

**Adversarial Research Sweep:**

| Item | Description | Status | Materiality |
|------|-------------|--------|-------------|
| **FCPA settlement (2023)** | $103M settlement with SEC/DOJ for pre-2010 anti-bribery violations in Vietnam, India, Indonesia. Self-reported, cooperated, paid disgorgement + penalty [S3] | Resolved with independent compliance monitor through ~2026 | Material historically; resolved |
| **Chile CORFO commission litigation risk** | No active litigation, but CORFO commissions paid ($232M in 2024) under tiered royalty structure; new Chile lithium law could alter terms post-2030 [S5] | Ongoing political risk | Material to long-term Chile resource access |
| **Short reports** | No known major short-seller report (Hindenburg, Muddy Waters, etc.) targeting ALB through May 2026 [S6] | None | N/A |
| **Class actions** | Standard securities class actions filed in 2024 related to lithium price disclosures (Kemerton ramp + capex guidance) — early-stage, no settlement [S7] | Ongoing | Likely immaterial individually |
| **Goodwill / asset impairments** | $1.03B (2024) + $280M (2025) — Kemerton Train 3 + Ketjen pre-sale marks; auditor-approved [S2] | Concluded | Non-cash; bookkeeping not concerning |
| **SBC creep** | $40M (2025); steady at 0.8% of revenue [S4] | Low | None |
| **Insider selling** | No significant insider selling at trough; equity-based comp vesting normal [S8] | Neutral | None |
| **Related-party transactions** | Standard JV arrangements (Talison with Tianqi/IGO; MARBL with Mineral Resources); arm's-length disclosed [S1] | None | None |
| **CFO turnover** | Stable; no recent CFO churn [S9] | None | None |

**Detailed FCPA notes:** The 2023 settlement related to payments made by intermediaries / agents to government officials in Vietnam, India, and Indonesia before 2010. Albemarle self-disclosed to DOJ in 2017–2018 and cooperated through investigation. The settlement included a deferred prosecution agreement (DPA), $103M in disgorgement + penalty, and a 2-year independent compliance monitorship (extending into 2026) [S3]. There is no evidence of repeat misconduct post-2010; the FCPA matter is contained, but creates ongoing reputational and regulatory monitoring overhead.

**Non-GAAP usage:** Albemarle reports adjusted EBITDA and adjusted EPS that exclude impairments, acquisition/divestiture-related items, and certain restructuring charges. The adjustments are clearly disclosed in earnings releases, and the magnitude of adjustments in 2024–2025 is large but documented [S10]. We will use adjusted EBITDA for cyclical comparison and GAAP net income for fundamental valuation.

#### Evidence and Sources

- OCF positive every year 2020–2025 even with GAAP losses — see xbrl_summary.md cash flow [S4].
- FCPA settlement $103M (2023) — public DOJ/SEC announcements [S3].
- Capex < D&A in 2025 ($590M vs. $659M) — discipline visible [S4].

#### Assumption Register Updates

| ID | Assumption | Change |
|----|-----------|--------|
| A06 | 2024 impairments drove ($1.18B) net loss | Confirmed; ~$1.03B of the loss was non-cash impairments |
| (new) A29 | OCF positive through the cycle ($702M+ even at trough) | Fact, Low sensitivity — anchors downside protection |
| (new) A30 | FCPA settlement risk premium: +50–100 bps to cost of equity | Judgment, Low sensitivity |

#### Tables and Calculations

**Earnings quality snapshot:**

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q1'26 |
|--------|--------|--------|--------|--------|----------|
| Net Income ($M) | 2,690 | 1,574 | (1,179) | (511) | (633) |
| OCF ($M) | 1,908 | 1,325 | 702 | 1,282 | 1,081 |
| OCF − NI ($M) | (782) | (249) | 1,881 | 1,793 | 1,714 |
| Impairments ($M) | 0 | 0 | 1,025 | 280 | 460 |
| Adj. Net Income (NI + Impair) | 2,690 | 1,574 | (154) | (231) | (173) |

The OCF-NI gap in 2024–2025 is almost entirely impairment-driven. Adjusted net income shows a much smaller actual loss footprint.

#### Open Questions and Data Gaps

1. Status of any FCPA-related residual obligations after monitorship ends (likely 2026).
2. Inventory carrying-value reserves at YE 2025 (vs. potential additional writedowns if lithium prices weaken again).
3. Class action status updates beyond initial complaints.

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | SEC 10-K FY2025 | Financial statements + notes | filed Feb 2026 | Accounting policies |
| [S2] | SEC 10-K FY2024 + FY2025 | Impairment notes | filed 2025/2026 | Kemerton + Ketjen marks |
| [S3] | proxy/governance_and_compensation.md | SEC Settlement section | 2026-05-27 | FCPA $103M (2023) |
| [S4] | xbrl_summary.md | Cash flow + capex | 2026-05-27 | OCF, capex, SBC |
| [S5] | industry/market_overview.md | Chile CORFO | 2026-05-27 | Royalty payments |
| [S6] | Web search (Tavily) | Short reports | 2026-05-27 | No major shorts identified |
| [S7] | SEC 10-Q Q1 2026 | Legal proceedings | filed May 2026 | Class action mentions |
| [S8] | proxy/insider_transactions.md | Insider activity | 2026-05-27 | No selling at trough |
| [S9] | proxy/governance_and_compensation.md | Executives | 2026-05-27 | Stable management |
| [S10] | SEC 8-K Q4 2025, Q1 2026 | Non-GAAP reconciliation | 2026 | Adjusted EBITDA / EPS bridge |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ALB/fundamental

## Navigation

- Overview: /stocks/ALB
- Financials (this page): /stocks/ALB/financials
- Thesis: /stocks/ALB/thesis
- Investment Memo: /stocks/ALB/memo
- Coverage universe: /stocks